XBI - ETF AI Analysis
Top Page
SPDR S&P BIOTECH ETF (XBI)
Rating:58Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past few months, showing solid recent momentum.
Top Holdings with Strong Gains
Many of the largest positions, including several biotech names, have posted strong year-to-date gains that support the fund’s overall performance.
Moderate Expense Ratio
The fund’s expense ratio is reasonable for a specialized biotech ETF, helping investors keep more of their returns compared with higher-cost options.
Negative Factors
Heavy Sector Concentration
Almost all assets are in the health care sector, specifically biotech, which increases the risk if this single industry faces a downturn.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little protection if the U.S. market or economy weakens.
High Industry Volatility
Biotech stocks can be very sensitive to drug trial results, regulation, and sentiment, which can lead to sharp price swings in the fund.
XBI vs. SPDR S&P 500 ETF (SPY)
AUM10.28B
RegionNorth America
Expense Ratio0.35%
Beta1.01
IssuerSPDR
Inception DateJan 31, 2006
Dividend Yield0.4%
Asset ClassEquity
Index TrackedS&P Biotechnology Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume10,525,310
30 Day Avg. Volume8,742,638
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
246.84Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering157
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XBI Summary
XBI is the SPDR S&P Biotech ETF, which follows the S&P Biotechnology Select Industry Index and focuses on U.S. biotech companies in the health care sector. It holds a wide mix of firms working on new drugs and medical treatments, from smaller players to well-known names like Moderna and Viking Therapeutics. Investors might consider XBI for growth potential and diversification within biotech, since it spreads money fairly evenly across many companies. However, biotech stocks can be very volatile and sensitive to news about drug trials and regulation, so the ETF’s price can move up and down sharply.
How much will it cost me?The SPDR S&P Biotech ETF (XBI) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This expense ratio is slightly higher than average because the fund is actively managed with an equal-weighted structure, which requires more frequent adjustments compared to passively managed ETFs.
What would affect this ETF?The SPDR S&P Biotech ETF (XBI) could benefit from advancements in biotechnology, such as breakthroughs in gene editing and personalized medicine, which drive innovation and growth in the sector. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding and investor sentiment in the biotech industry.
XBI Top 10 Holdings
XBI is a pure play on U.S. biotech, and its story right now is all about volatility at the cutting edge of medicine. High-profile names like Moderna and Natera are rising, helping to pull the fund higher as investors warm back up to innovative therapies and diagnostics. Established giants such as Amgen, AbbVie, and Gilead are steadier anchors, adding some ballast but not shooting the lights out. Meanwhile, Twist Bioscience and TG Therapeutics show more mixed, sometimes lagging action, reminding investors that this equal-weight biotech basket can be a bumpy ride.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 2.59% | $259.36M | $94.42B | 738.18% | 59 Neutral | |
| Natera | 1.85% | $185.73M | $58.35B | 116.54% | 73 Outperform | |
| Twist Bioscience | 1.83% | $183.45M | $9.51B | 369.89% | 43 Neutral | |
| AbbVie | 1.75% | $175.61M | $500.80B | 24.33% | 66 Neutral | |
| Biogen | 1.71% | $171.72M | $34.77B | 62.69% | 74 Outperform | |
| Amgen | 1.69% | $169.27M | $234.65B | 44.74% | 77 Outperform | |
| Halozyme | 1.69% | $169.06M | $13.79B | 81.77% | 73 Outperform | |
| Iovance Biotherapeutics | 1.68% | $168.15M | $6.67B | 524.77% | 50 Neutral | |
| United Therapeutics | 1.65% | $165.62M | $23.23B | 23.02% | 79 Outperform | |
| Gilead Sciences | 1.63% | $163.84M | $195.13B | 27.18% | 78 Outperform |
XBI Technical Analysis
Negative
―
Price Trends
157.96
Negative
152.44
Negative
140.08
Positive
Market Momentum
-2.96
Positive
35.91
Neutral
17.61
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XBI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 153.29, equal to the 50-day MA of 157.96, and equal to the 200-day MA of 140.08, indicating a neutral trend. The MACD of -2.96 indicates Positive momentum. The RSI at 35.91 is Neutral, neither overbought nor oversold. The STOCH value of 17.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBI.
XBI Peer Comparison
Comparison Results
Performance Comparison
XBI
SPDR S&P BIOTECH ETF
144.32
34.62
31.56%
VGT
Vanguard Information Technology ETF
―
―
―
XLK
Technology Select Sector SPDR Fund
―
―
―
XLV
Health Care Select Sector SPDR Fund
―
―
―
VHT
Vanguard Health Care ETF
―
―
―
IBB
iShares Biotechnology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents